CSIMarket
 
Aslan Pharmaceuticals Limited  (ASLN)
Other Ticker:  
 
 
Price: $0.7995 $0.15 23.000%
Day's High: $0.8 Week Perf: 16.72 %
Day's Low: $ 0.64 30 Day Perf: 41.98 %
Volume (M): 1,773 52 Wk High: $ 4.69
Volume (M$): $ 1,418 52 Wk Avg: $2.01
Open: $0.68 52 Wk Low: $0.39



 Market Capitalization (Millions $) 274
 Shares Outstanding (Millions) 343
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -51
 Cash Flow (TTM) (Millions $) 90
 Capital Exp. (TTM) (Millions $) 0

Aslan Pharmaceuticals Limited
Aslan Pharmaceuticals Limited is a biopharmaceutical company that focuses on the development of innovative therapeutics for oncology and immunology. They utilize precision medicine approaches to develop targeted therapies for patients with unmet medical needs. Aslan Pharmaceuticals has a diverse pipeline of drug candidates, including both small molecule and antibody therapies. They collaborate with leading academic institutions and research organizations to advance their drug development programs.


   Company Address: 3 Temasek Avenue Level 18 Centennial Tower Singapore 39190
   Company Phone Number: 6817 9598   Stock Exchange / Ticker: NASDAQ ASLN
   ASLN is expected to report next financial results on March 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering, Set to Transform Immunology Treatments

Published Tue, Mar 12 2024 6:35 PM UTC



SAN MATEO, Calif. and SINGAPORE, March 12, 2024 ?? ASLAN Pharmaceuticals Ltd., a prominent immunology focused biopharmaceutical company, recently revealed plans for a landmark $5 million registered direct offering. The company aims to develop innovative treatments and positively impact patients' lives. Concurrently, ASLAN will issue unregistered warrants in a priva...

Clinical Study

ASLAN Pharmaceuticals' TREK-DX Study Update: Eblasakimab Shows Promise in Dupilumab-Experienced Atopic Dermatitis Patients

Published Mon, Mar 11 2024 11:00 AM UTC

ASLAN Pharmaceuticals, a leading biopharmaceutical company focused on immunology, has recently provided an important update regarding its ongoing TREK-DX trial. The study aims to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe atopic dermatitis (AD), who have prior experience with the medication dupilumab. This article aims to outline the ...

Product Service News

ASLAN Pharmaceuticals Reports Positive Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts to Scientific Advisory Board

Published Wed, Mar 6 2024 12:01 PM UTC

ASLAN Pharmaceuticals Announces Positive Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific AdvisorsSan Mateo, Calif. and Singapore ?? March 06, 2024 ?? ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage biopharmaceutical company focused on immunology, has unveiled new promising translational data from a head-to-head stu...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com